22930-71-8

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, hydrazone (9CI) is used as a precursor for the synthesis of various bioactive compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
4(1H)-Pyrimidinone, hydrazone (9CI) is used as a building block in the synthesis of agrochemicals, such as pesticides and herbicides, to enhance crop protection and yield.
Used in Organic Synthesis:
4(1H)-Pyrimidinone, hydrazone (9CI) is used as a versatile intermediate in organic synthesis, enabling the production of a wide range of chemical products.
Used in Antimicrobial Applications:
4(1H)-Pyrimidinone, hydrazone (9CI) is studied for its potential antimicrobial properties, which could be utilized in the development of new antimicrobial agents to combat resistant bacteria and other pathogens.
Used in Antimalarial Applications:
4(1H)-Pyrimidinone, hydrazone (9CI) is studied for its potential antimalarial properties, which could be harnessed in the development of new treatments for malaria.
Used in Antitumor Applications:
4(1H)-Pyrimidinone, hydrazone (9CI) is studied for its potential antitumor properties, which could be utilized in the development of new cancer therapies.
However, further research and development are needed to fully understand and harness the potential of 4(1H)-Pyrimidinone, hydrazone (9CI) for various industrial and pharmaceutical applications.

Upstream product

• 6104-41-2 4-methoxypyrimidine 
• 5767-35-1 6-chloro-4-hydrazinopyrimidine 
• 52476-87-6 (2-chloropyrimidin-4-yl)hydrazine 

Relevant academic research and scientific papers

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity

A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75- 1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more potent (IC50 = 0.011-0.436 μM) than the ribonucleotide reductase inhibitor hydroxyurea (IC50 = 140 μM). Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC50 of 0.011-0.035 μM. [14C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [14C]cytidine incorporation to a greater extent (IC50 = 0.67-5.05 μM) than the Z-isomers (IC50 = 7.20 to > 10 μM). Principal component analysis of the IC50 values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].